AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7019785
Drug: Sodium selenite
RxNorm normalized name: Sodium selenite
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Sodium selenite or selenomethionine (100 micrograms Se daily)
Trial: 23058029
Drug: Amoxicillin and
RxNorm normalized name: omeprazole, amoxicillin and rifabutin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin and clavulanic acid
Trial: 17473143
Drug: Chemoprophylaxis plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoprophylaxis plus intermittent pneumatic compression (more than six hours daily)
Trial: 15148925
Drug: Celecoxib 200
RxNorm normalized name: celecoxib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib 200 mg daily (qd) for 6 weeks
Trial: 15148925
Drug: Celecoxib 200
RxNorm normalized name: celecoxib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib 200 mg twice a day (bid) for 6 weeks
Trial: 11939160
Drug: Gonadotrophin-releasing hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gonadotrophin-releasing hormone agonists (buserelin, leuprolide, triptorelin)
Trial: 9690949
Drug: Itraconazole 100
RxNorm normalized name: itraconazole 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole 100 mg orally once daily for 4 days
Trial: 7866002
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment (points ST36, LI11, RN6, and symptomatic points bilaterally) for 30 minutes daily for 10 days
Trial: 2562387
Drug: Guar gum
RxNorm normalized name: Guar Gum
DrugBank: Guar gum (DB13446)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guar gum (15 g/day, divided in three doses with major meals)
Trial: 18060379
Drug: TCR occurrence
RxNorm normalized name: AUTOLOGOUS CD4+ AND CD8+ T CELLS OBTAINED BY LEUKAPHERESIS, TRANSDUCED WITH AN HIV-DERIVED SELF-INACTIVATING (SIN) LENTIVIRAL VECTOR, ENCODING AN ENHANCED-AFFINITY T CELL RECEPTOR (TCR) SPECIFIC FOR THE HUMAN MELANOMA ANTIGEN A4 (MAGE FAMILY MEMBER A4, A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TCR occurrence during nasal mucosa preparation
Trial: 16764647
Drug: Celecoxib 200
RxNorm normalized name: celecoxib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib 200 mg twice daily for 14 days
Trial: 12971705
Drug: Routine therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine therapy (RT) group received no professional rehabilitation therapy
Trial: 11033383
Drug: Dose-response studies
RxNorm normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dose-response studies in Phase I
Trial: 11033383
Drug: Dose-response studies
RxNorm normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dose-response studies in Phase II
Trial: 11033383
Drug: Dose-response assessment
RxNorm normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dose-response assessment
Trial: 9436670
Drug: Intravenous immunoglobulins
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulins (Ig) administered between weeks 5 and 7 of gestation for 2 consecutive days, with a further infusion at week 8.
Trial: 9436670
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered between weeks 5 and 7 of gestation for 2 consecutive days, with a further infusion at week 8.
Trial: 8292687
Drug: Intravenous clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous clonidine hydrochloride (2 micrograms/kg)
Trial: 3538478
Drug: Metered dose
RxNorm normalized name: Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metered dose inhaler with conical spacer device
Trial: 3538478
Drug: Metered dose
RxNorm normalized name: Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metered dose inhaler without conical spacer device
Trial: 3538478
Drug: Nebuliser treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebuliser treatment
Trial: 20299485
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg aspirin once daily
Trial: 24213952
Drug: Late parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late parenteral nutrition (PN) starting on day 8
Trial: 17320568
Drug: 20% mannitol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% mannitol 0.5 g/kg
Trial: 17320568
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline 2.5 mL/kg
Trial: 11007673
Drug: Supine position
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supine position (Diuretic)
Trial: 11007673
Drug: Upright position
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Upright position (Diuretic)
Trial: 6378422
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (nitrates and beta-blockers)
Trial: 3511709
Drug: Erythromycin (333
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (333 mg three times daily by mouth for 7 days)
Trial: 23615499
Drug: Intravenous methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous methylprednisolone (IV MeP)
Trial: 21322282
Drug: Ganciclovir (induction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ganciclovir (induction and maintenance treatment)
Trial: 9200528
Drug: Paroxetine doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine doses ranged from 10 to 40 mg/day
Trial: 1555692
Drug: Long protocol
RxNorm normalized name: long pepper extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long protocol (subcutaneous buserelin acetate 200 micrograms/d from day 1, hMG started after 14 days)
Trial: 1555692
Drug: Short protocol
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short protocol (subcutaneous buserelin acetate 200 micrograms/d from day 2, hMG from day 3)
Trial: 3904102
Drug: Methylprednisolone (MPN)
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (MPN) 375 mg administered in 3 equal doses IV just prior to chemotherapy and then IM 6 and 12 hours after treatment
Trial: 3904102
Drug: Metoclopramide (MCP)
DrugBank: Metoclopramide (DB01233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metoclopramide (MCP) 1 mg/kg administered in 3 equal doses IV just prior to chemotherapy and then IM 6 and 12 hours after treatment
Trial: 30107488
Drug: 120 g
RxNorm normalized name: soap 120 gram TOPICAL BAR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 g full-fat Irish cheddar cheese (FFCC)
Trial: 30107488
Drug: Butter (49
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butter (49 g), calcium caseinate powder (30 g), and Ca supplement (CaCO3) (500 mg) (BCC)
Trial: 30107488
Drug: 120 g
RxNorm normalized name: soap 120 gram TOPICAL BAR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 g reduced-fat Irish cheddar cheese + butter (21 g) (RFC + B)
Trial: 30107488
Drug: 120 g
RxNorm normalized name: soap 120 gram TOPICAL BAR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 g FFCC (as per A) after a 6-wk run-in period
Trial: 25481088
Drug: Intramuscular testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular testosterone administration once per week for 8 weeks starting 2 weeks prior to surgery
Trial: 18511650
Drug: Abetimus sodium
RxNorm normalized name: abetimus sodium
DrugBank: Abetimus (DB06662)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abetimus sodium 600 mg
Trial: 18511650
Drug: Abetimus sodium
RxNorm normalized name: abetimus sodium
DrugBank: Abetimus (DB06662)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abetimus sodium 1200 mg
Trial: 18511650
Drug: Abetimus sodium
RxNorm normalized name: abetimus sodium
DrugBank: Abetimus (DB06662)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abetimus sodium 2400 mg
Trial: 18511650
Drug: All doses
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All doses of abetimus sodium
Trial: 16425357
Drug: Combined medication
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined medication (Control group)
Trial: 12874182
Drug: Lotrafiban 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lotrafiban 30 or 50 mg BID
Trial: 12874182
Drug: Aspirin >162
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin >162 mg/d
Trial: 10649829
Drug: Sumatriptan (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sumatriptan (6 mg SQ)
Trial: 8657986
Drug: Valerian and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valerian and hops tablets
Trial: 8657986
Drug: Valerian syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valerian syrup
Trial: 8281625
Drug: Droloxifene 20
RxNorm normalized name: Droloxifene
DrugBank: Droloxifene (DB15641)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droloxifene 20 mg
Trial: 8281625
Drug: Droloxifene 40
RxNorm normalized name: Droloxifene
DrugBank: Droloxifene (DB15641)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droloxifene 40 mg
Trial: 8281625
Drug: Droloxifene 100
RxNorm normalized name: Droloxifene
DrugBank: Droloxifene (DB15641)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droloxifene 100 mg
Trial: 1515258
Drug: Droloxifene (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droloxifene (all doses)
Trial: 6394143
Drug: Tolfenamic acid
RxNorm normalized name: Tolfenamic acid
DrugBank: Tolfenamic acid (DB09216)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolfenamic acid (200 mg)
Trial: 6394143
Drug: Tolfenamic acid
RxNorm normalized name: Tolfenamic acid
DrugBank: Tolfenamic acid (DB09216)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolfenamic acid + Caffeine (200 mg + 100 mg)
Trial: 6394143
Drug: Tolfenamic acid
RxNorm normalized name: Tolfenamic acid
DrugBank: Tolfenamic acid (DB09216)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolfenamic acid + Metoclopramide (200 mg + 10 mg)
Trial: 31032783
Drug: Topical minoxidil
RxNorm normalized name: MINOXIDIL 50 mg in 1 mL TOPICAL SOLUTION [Stafenit Hair Regrowth Treatment Topical Minoxidil]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical minoxidil 5% lotion applied twice daily
Trial: 31032783
Drug: Mesotherapy injected
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mesotherapy injected once weekly
Trial: 24657006
Drug: Group cognitive-behavioral
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group cognitive-behavioral therapy (module theme: people-themed)
Trial: 24657006
Drug: Group cognitive-behavioral
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group cognitive-behavioral therapy (module theme: thoughts-themed)
Trial: 21851027
Drug: PCEA with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCEA with 0.125% bupivacaine and fentanyl (2 mcg/ml) with adrenaline (2 mcg/ml) (ABF group)
Trial: 21851027
Drug: PCEA with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCEA with 0.125% bupivacaine and fentanyl (2 mcg/ml) without adrenaline (BF group)
Trial: 19138601
Drug: Moxifloxacin (MXF)
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moxifloxacin (MXF) 400 mg/24 hours for 5 days
Trial: 19138601
Drug: Amoxicillin and
RxNorm normalized name: omeprazole, amoxicillin and rifabutin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin and clavulanic acid (AMX-CLV) 500/125 mg/8 hours for 5 days
Trial: 11230488
Drug: High-dose interferon
RxNorm normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose interferon alfa-2b (IFNalpha2b)
Trial: 11230488
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of high-dose interferon alfa-2b (IFNalpha2b) and GMK
Trial: 9021810
Drug: Three-drug regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-drug regimen during induction therapy
Trial: 7950332
Drug: Norfloxacin (0.3%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norfloxacin (0.3% solution, 50 ul)
Trial: 7950332
Drug: Ofloxacin (same
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin (same dose as norfloxacin)
Trial: 3296435
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of radiation and hormonotherapy (17-hydroxyprogesterone caproate)
Trial: 28738794
Drug: Pharmacotherapy combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacotherapy combined with psychoeducation
Trial: 23453611
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg dexamethasone as submucosal injection
Trial: 19117731
Drug: Teicoplanin (10mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teicoplanin (10mg/kg single dose upon introduction of anaesthesia)
Trial: 19117731
Drug: Comparator (multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparator (multiple doses of broad-spectrum antimicrobials for 4-6 days)
Trial: 16645021
Drug: Lipid-heparin emulsion
RxNorm normalized name: propofol lipid emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-heparin emulsion (LHE) infusion
Trial: 17381494
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (NaCl 0.9%) infusion (control)
Trial: 11394552
Drug: Major and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Major and minor stress assessment using Life Experiences Survey and Weekly Stress Inventory
Trial: 9932220
Drug: Antibiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic treatment (amoxicillin‐clavulanic acid, 1.5 g/24 h for 10 days)
Trial: 8563533
Drug: Mixed therapy
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed therapy (deep breathing exercises for low risk patients and incentive spirometry plus physiotherapy for high risk patients)
Trial: 1546725
Drug: Trimipramine 25
RxNorm normalized name: trimipramine 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimipramine 25 mg
Trial: 28921781
Drug: VGCV for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VGCV for 100 days followed by 3 doses of monthly CMV HIG
Trial: 25817172
Drug: Intravitreal ranibizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal ranibizumab (IVR) injection
Trial: 25817172
Drug: Focal/grid laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Focal/grid laser treatment
Trial: 18289149
Drug: Continuous paroxetine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous paroxetine treatment (20 mg daily)
Trial: 18289149
Drug: Intermittent paroxetine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent paroxetine treatment (20 mg daily)
Trial: 17044464
Drug: Oral isosorbide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral isosorbide 5-mononitrate (ISMN) 20 mg bid for 5 days
Trial: 7918123
Drug: Sequential treatment:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential treatment: three courses of neoadjuvant chemotherapy with cisplatin (100 mg/m2 i.v. d 1) and 5‐fluorouracil (1000 mg/m2/days 1‐5 by continuous i.v. infusion every 3 weeks) followed by conventional radiotherapy of 65‐70 Gy.
Trial: 7918123
Drug: Simultaneous treatment:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simultaneous treatment: cisplatin (100 mg/m2 on days 1, 22, 43) given simultaneously with conventional radiotherapy of 65‐70 Gy.
Trial: 29855294
Drug: Simultaneous treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simultaneous treatment
Trial: 2460431
Drug: Cockroach antigen
RxNorm normalized name: American cockroach allergenic extract
DrugBank: Periplaneta americana (DB10417)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cockroach antigen immunotherapy (CRa‐IT)
Trial: 2460431
Drug: Control immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control immunotherapy (control-IT)
Trial: 12396323
Drug: Albendazole 400
RxNorm normalized name: albendazole 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albendazole 400 mg
Trial: 29611504
Drug: Placebo (similar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (similar placebo tablet)
Trial: 23834882
Drug: Interactive educational
RxNorm normalized name: DIABETES PATIENT EDUCATION PACK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interactive educational seminar on antibiotic prescription for respiratory infections
Trial: 21997904
Drug: Saline irrigation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline irrigation plus separate budesonide nasal spray (group B)
Trial: 21997904
Drug: Saline irrigation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline irrigation mixed with budesonide nasal spray (group C)
Trial: 18477935
Drug: rhGH (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhGH (0.2 mg/kg/day) and propranolol (to decrease heart rate by 15%) for > or = 15 days
Trial: 16503537
Drug: 0.125% levobupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.125% levobupivacaine and 20 microg/ml morphine (group L)
Trial: 16503537
Drug: 0.125% ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.125% ropivacaine and 20 microg/ml morphine (group R)
Trial: 16503537
Drug: 0.125% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.125% bupivacaine and 20 microg/ml morphine (group B)
Trial: 14551548
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.25% bupivacaine solution infusion catheter
Trial: 14551548
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion catheter
Trial: 10620552
Drug: Bicarbonate-buffered peritoneal
RxNorm normalized name: Potassium Bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bicarbonate-buffered peritoneal dialysis fluid (TB; 38 mmol/L of bicarbonate; pH 7.3)
Trial: 10620552
Drug: Bicarbonate/lactate-buffered peritoneal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bicarbonate/lactate-buffered peritoneal dialysis fluid (TBL; 25 mmol/L of bicarbonate/15 mmol/L of lactate; pH 7.3)
Trial: 10620552
Drug: Acidic lactate-buffered
RxNorm normalized name: lactate / salicylic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acidic lactate-buffered peritoneal dialysis fluid (PD4; 40 mmol/L of lactate; pH 5.2)
Trial: 30782886
Drug: TRAM/DKP 75/25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRAM/DKP 75/25 mg
Trial: 30782886
Drug: TRAM/paracetamol 75/650
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRAM/paracetamol 75/650 mg
Trial: 28285318
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg bupivacaine (Group S1)
Trial: 28285318
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg bupivacaine (Group S2)
Trial: 18241321
Drug: XR‐NTX 190
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XR‐NTX 190 mg
Trial: 16682719
Drug: Dose-dense chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-dense chemotherapy regimens
Trial: 1349294
Drug: Infusion study
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Infusion study in persons with mild hypothyroidism (saline or 10% dextrose)
Trial: 6530305
Drug: Alteration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alteration of nicotine level (specific dosage and duration not provided)
Trial: 30772385
Drug: Lixisenatide +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lixisenatide + Basal Insulin (BI)
Trial: 30772385
Drug: Sulfonylurea +
RxNorm normalized name: sulfanilylurea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfonylurea + Basal Insulin (BI)
Trial: 28963845
Drug: Kangle Decoction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kangle Decoction at 0.5 dose bid for 8 weeks
Trial: 28963845
Drug: Cialis at
RxNorm normalized name: Cialis
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cialis at 10 mg qd alt for 8 weeks
Trial: 25070961
Drug: ropinirole +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ropinirole + physical therapy
Trial: 25070961
Drug: placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo + physical therapy
Trial: 22551324
Drug: topical nipradilol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical nipradilol
Trial: 2904203
Drug: topical timolol
RxNorm normalized name: timolol
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: topical timolol
Trial: 22551324
Drug: topical β-blocker
RxNorm normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: topical β-blocker (nipradilol or timolol)
Trial: 20386073
Drug: Zidovudine 200
RxNorm normalized name: zidovudine 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zidovudine 200 mg